ArticleMedicine2026
Association of Endothelial Activation and Stress Index (EASIX) with long-term mortality in type 2 diabetes patients with coronary heart disease: A prospective national cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endothelial dysfunction is prevalent in type 2 diabetes mellitus (T2DM) with coronary heart disease (CHD), increasing cardiovascular risk. The Endothelial Activation and Stress Index (EASIX) is a novel composite biomarker, yet its prognostic value in this comorbid population remains unclear. In this prospective cohort study, we analyzed 909 participants with T2DM and CHD from National Health and Nutrition Examination Survey 1999 to 2010, followed until 2019. EASIX was calculated using lactate dehydrogenase, creatinine, and platelet count. Multivariable Cox regression and Fine-Gray competing-risk models assessed associations between EASIX and all-cause and cardiovascular mortality, respectively. Time-dependent C-statistic, net reclassification improvement, and integrated discrimination improvement evaluated the incremental prognostic value of EASIX beyond established risk factors. During a median follow-up of 111 months, 617 all-cause and 251 cardiovascular deaths occurred. Higher EASIX levels were significantly associated with increased mortality risks. In fully adjusted models, the highest quartile had a hazard ratio of 1.93 (95% confidence interval = 1.48-2.50) for all-cause mortality and a subdistribution hazard ratio of 1.56 (95% confidence interval = 1.05-2.33) for cardiovascular mortality compared with the lowest quartile. Restricted cubic spline analysis revealed a significant nonlinear positive relationship. Adding EASIX to a base model (age, HbA1c, and estimated glomerular filtration rate) significantly improved the C-statistic, net reclassification improvement, and integrated discrimination improvement for both outcomes (all P < .001). Elevated EASIX levels are independently associated with higher all-cause and cardiovascular mortality in patients with T2DM and CHD. In this population, its inclusion in risk assessment protocols enhances the predictive value for long-term clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.